Eagle Pharmaceuticals, Inc. EGRX Income Statement

Eagle pharmaceuticals, inc. (EGRX)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Jun'13	Mar'13
Revenue:
Total revenue
192,127	195,892	203,687	213,877	216,471	213,312	204,044	215,728	206,540	236,707	271,062	245,874	236,684	189,482	126,522	94,425	59,509	66,227	53,647	50,722	50,512	19,208	19,100	21,364	18,052	0	0	0
Operating expenses:
Cost of product sales
43,102	47,891	52,322	48,806	44,705	42,374	39,142	35,336	30,172	33,714	34,327	35,512	33,783	35,785	0	0	0	-	-	-	-	0	-	-	-	-	-	-
Cost of royalty revenue
12,498	13,006	15,542	17,127	18,503	19,542	17,923	20,403	20,828	23,472	27,971	25,546	24,928	19,521	5,375	4,703	3,759	7,885	15,756	14,178	12,386	9,798	11,715	12,465	12,222	0	0	0
Research and development
39,862	36,810	31,363	27,166	33,474	44,419	48,004	50,983	42,402	32,607	38,925	33,178	30,293	28,289	21,308	25,012	27,091	27,855	23,060	22,037	20,704	18,213	16,816	12,560	10,540	0	0	0
Selling, general and administrative
82,984	76,370	69,357	64,698	63,457	60,509	57,947	60,738	68,031	71,416	76,077	71,069	59,779	53,329	41,387	35,186	28,307	20,165	18,247	16,641	14,203	11,671	9,325	6,722	6,997	0	0	0
Restructuring charge
-	-	0	0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of asset
-	-	-	-	-	-	-	-	-	-	-	-	-	1,750	1,750	1,750	1,750	0	0	0	0	0	-	-	-	-	-	-
Asset impairment charge
-	-	0	0	-	-	0	0	-	-	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of contingent consideration
-	-	0	0	-	-	0	0	-	-	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
178,446	174,077	169,043	158,347	169,991	176,696	172,712	177,848	162,941	162,717	179,230	166,684	149,740	136,131	100,262	90,861	77,936	63,667	58,845	54,638	49,075	41,464	37,856	29,754	27,767	0	0	0
Professional fee benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Income from operations
13,681	21,815	34,644	55,530	46,480	36,616	31,332	37,880	43,599	73,990	91,832	79,190	86,944	53,351	26,260	3,564	-18,427	2,560	-5,198	-3,916	1,437	-22,256	-18,756	-8,390	-9,714	0	0	0
Interest income
2,021	2,169	1,822	1,261	625	158	76	102	115	91	59	50	66	84	79	61	39	25	24	20	30	31	31	28	10	0	0	0
Interest expense
2,889	2,686	2,596	2,711	2,747	2,736	2,661	2,445	1,784	1,136	0	0	0	-	-	-	10	11	10	7	9	9	8	22	161	0	0	0
Amortization of deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Amortization of debt discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Change in value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	383	574	589	589	0	0	0
Other expense
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0
Total other expense, net
-6,668	183	-774	-1,450	-2,122	-2,578	-2,585	-2,343	-1,669	-1,045	-536	-21	32	76	70	50	28	14	14	13	56	-326	-516	-1,023	-1,568	0	0	0
(Loss) Income before income tax benefit (provision)
7,013	21,998	33,870	54,080	44,358	34,038	28,747	35,537	41,930	72,945	91,296	79,169	86,976	53,427	26,330	3,614	-18,399	2,574	-5,184	-3,903	1,493	-22,582	-19,272	-9,413	-11,283	0	0	0
Income tax benefit (provision)
4,544	7,685	7,974	11,754	6,098	2,135	347	5,746	10,295	21,002	-8,860	-17,508	-18,297	-28,026	957	360	-377	3	-1,031	-813	-660	-2,354	-1,295	-1,295	-1,295	0	0	0
Less dividends on Series A, B, B-1 and C Convertible Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	534	1,666	2,740	3,551	0	0	0
Net income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-20,762	-19,643	-10,859	-13,539	0	0	0
Net (Loss) Income
2,469	14,313	25,896	42,326	38,260	31,903	28,400	29,791	31,635	51,943	100,156	96,677	105,273	81,453	25,373	3,254	-18,022	2,571	-4,153	-3,090	2,153	-20,228	-17,977	-8,118	-9,988	0	0	0
(Loss) Earnings per share attributable to common stockholders:
Basic (in usd per share)
-0.21	0.08	-0.17	0.49	0.64	0.86	0.94	0.18	0.18	0.61	1.03	0.30	1.50	3.69	0.77	0.84	-0.06	-0.03	-0.65	-0.53	1.38	-0.39	-0.65	-0.21	-0.36	-1.44	-	-
Diluted (in usd per share)
-0.21	0.08	-0.17	0.48	0.62	0.84	0.91	0.17	0.17	0.59	0.98	0.28	1.42	3.49	0.73	0.80	-0.06	0.03	-0.65	-0.53	1.31	-0.39	-0.65	-0.21	-0.36	-1.44	-	-
Weighted average number of common shares outstanding:
Basic (in shares)
13,667	13,642	13,668	13,782	13,925	14,364	15,011	14,879	14,819	14,885	15,047	15,219	15,257	15,291	15,570	15,636	15,636	15,616	15,589	15,546	14,247	14,032	14,021	14,020	8,862	-	-	-
Diluted (in shares)
13,667	14,312	13,668	14,156	14,418	14,706	15,483	15,446	15,478	15,602	15,764	16,100	16,165	17,183	16,450	16,466	15,636	18,837	15,589	15,546	15,041	14,032	14,021	14,020	8,862	-	-	-
Loss per share attributable to common stockholders Basic and diluted (in usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.11	-1.84
Weighted average common shares outstanding Basic and diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,048	3,048
Product sales
Total revenue
77,211	73,989	78,911	80,415	74,019	70,385	0	51,216	40,879	45,327	43,975	44,907	41,810	40,646	34,434	29,911	24,034	12,968	11,606	9,169	5,789	3,908	4,626	6,238	6,833	0	0	0
Royalty revenue
Total revenue
114,916	112,903	115,776	124,462	133,452	142,927	0	152,012	153,161	153,880	149,541	132,171	126,078	99,040	67,338	43,514	14,475	8,259	12,041	11,553	11,223	11,535	10,709	11,360	10,954	0	0	0
License and other revenue
Total revenue
0	9,000	9,000	9,000	9,000	0	0	12,500	12,500	37,500	77,546	68,796	68,796	49,796	24,750	21,000	21,000	45,000	30,000	30,000	33,500	3,765	0	0	0	-	0	0